Results 201 to 210 of about 1,168,324 (310)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Leadership in immuno-oncology network 2 (LION:2) immunotherapy oncology - A present status

, 2019
Prashant Mehta, Vineet Talwar, Ankur Bahl   +2 more
openalex   +1 more source

Oncology nurses’ perceptions of work stress and its sources in a university‐teaching hospital: A qualitative study [PDF]

, 2018
Dhuha Youssef Wazqar
openalex   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Retraction: The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480

Pathology and Oncology Research
Pathology and Oncology Research Editorial Office
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

The Oncology Care Model: Oncology\u27s First Foray Away From Volume and Toward Value-Based Care. [PDF]

, 2019
Csik, Valerie P., Leader, Amy, Maio, Vittorio, Song, Andrew   +3 more
core   +1 more source

Oncology in obstetrics – a myth or a reality?

, 2019
V.L. Dronova, О.І. Dronov, О.М. Mokryk, L. O. Rochina, Yu.P. Bakunets   +4 more
openalex   +1 more source

Carboplatin is effective therapy for young children with progressiveoptic pathway tumors: A Pediatric Oncology Group phase II study [PDF]

, 2000
Donald H. Mahoney, Michael E. Cohen, Henry S. Friedman, James L. Kepner, Linda S. Gemer, J. William Langston, Hector E. James, Patricia K. Duffner, Larry E. Kun   +8 more
openalex   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source